Background: Brainstem gliomas have a short survival time; chemotherapy has not improved outcome. We report the result obtained with the combination of Radiotherapy and the monoclonal antibody Nimotuzumab in a series of these tumors. Material and methods: 40 children and adolescents treated with irradiation and Nimotuzumab were included between Jan 2009 and December 2015, all with the diagnosis of diffuse infiltrative pontine gliomas (DIPG), irradiated at the Instituto Nacional de Oncologia y Radiobiologia, in Havana, Cuba. Nimotuzumab was applied during the period receiving Radiotherapy and them monthly for one year or more. Results: Median age at diagnosis was 7,9 years (range 3-18 years old); median survival was 18,4 months and Kaplan Meier survival was 42,5% at 2 years and 34,5% at 5 years, established till 9 years. Addition of Nimotuzumab was safe and well tolerated. Conclusion: Combination of Nimotuzumab and Radiotherapy is safe and could increase survival
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.